Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Standard BioTools, Inc. (LAB)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
$0.62+1.04%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for LAB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Capital allocation supports growth without excessive dilution | A supporting condition in Standard BioTools, Inc.'s published investment case. The stated target is Capital raises limited and aligned with merger needs in 2026. | Intact | Excessive equity dilution beyond merger-related needs | No excessive dilution reported Confirmed merger with Treeline Biosciences and completed Multiplex Bio acquisition support growth strategy without excessive dilution. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, execution-sensitive business with a sector tailwind, rather than a steady compounder. The long-term thesis is intact, while the signal has turned cautious and management execution remains volatile.
LAB is cheap versus peers, and valuation has fallen sharply in recent changes. The evidence suggests the market reflects weak execution quality, but not the full combination of expensive valuation, weak execution, and turbulence; expectations are also below the model’s reference level.
Near term, first-half 2026 revenue was roughly half of the original full-year guidance, but management later withdrew that outlook because of the pending merger. The Treeline merger remains on track for end-2026, subject to stockholder approval, while smaller-company risks and declining earnings surprises leave execution fragile.
The multi-year view depends in part on completing the Treeline merger and showing that the business can sustain revenue progress despite the withdrawn outlook. Near-term risks include a guidance cut and further weakening in jobs data, while continued strong results from sector peers could support the sector backdrop.
Over the next 1 to 3 years, LAB’s thesis is intact but uncertain: peer-relative cheapness and a sector tailwind are balanced by fragile execution, high risk, and merger-related uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful integration of Treeline Biosciences merger |
| The merger with Treeline Biosciences supports this growth plan. |
| Improving |
| Merger fails to close or integration stalls significantly |
Merger announced Jun 2026; integration progressing News confirms Treeline merger announcement and strategic rationale. M&A activity shows active deal execution and integration steps. Nov 5, 2026Last status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “Recent Highlights: • Second quarter 2026 revenue of $20.1 million • 1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year • Merger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.” Delivery assessment Nov 5, 2026 |
Revenue reaches approximately $82.5 million in FY26 | A primary condition in Standard BioTools, Inc.'s published investment case. The stated target is ~$82.5 million. | Intact | Revenue falls below $80 million in FY26 | Revenue: $19.385M FY2026-Q3; GAAP. Published target: ~$82.5 million. Annual target cannot be compared with a quarterly or TTM observation. Nov 3, 202619,385,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 3 supplied quarters. Management reported: “Recent Highlights: • Second quarter 2026 revenue of $20.1 million • 1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year • Merger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026 “We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools.” Delivery assessment Nov 5, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.09 → $-0.16 · observed estimates
$0.08B → $0.08B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-07-25 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-07-26 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-07-27 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-07-28 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-07-29 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-07-30 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-07-31 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-01 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-02 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-03 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-04 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-05 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-06 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-07 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-08 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-09 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-10 | $-0.01 | $84,100,000 | 1 / 2 |
| 2026-08-12 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-13 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-14 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-15 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-16 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-17 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-18 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-19 | $-0.09 | $84,089,650 | 1 / 1 |
| 2026-08-20 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-21 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-22 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-23 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-24 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-25 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-26 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-27 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-28 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-29 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-30 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-08-31 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-01 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-02 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-03 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-04 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-05 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-06 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-07 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-08 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-09 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-10 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-11 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-12 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-13 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-14 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-15 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-16 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-17 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-18 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-19 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-20 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-21 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-22 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-23 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-24 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-25 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-26 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-27 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-28 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-29 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-09-30 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-01 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-02 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-03 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-04 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-05 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-06 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-07 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-08 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-09 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-10 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-11 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-12 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-13 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-14 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-15 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-16 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-17 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-18 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-19 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-20 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-21 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-22 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-23 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-24 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-25 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-26 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-27 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-28 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-29 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-30 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-10-31 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-11-01 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-11-02 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-11-03 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-11-04 | $-0.16 | $82,100,000 | 1 / 1 |
| 2026-11-05 | $-0.16 | $82,100,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 0 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
1 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.